<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01687998</url>
  </required_header>
  <id_info>
    <org_study_id>11949</org_study_id>
    <secondary_id>I1V-MC-EIAN</secondary_id>
    <nct_id>NCT01687998</nct_id>
  </id_info>
  <brief_title>A Study of Evacetrapib in High-Risk Vascular Disease</brief_title>
  <acronym>ACCELERATE</acronym>
  <official_title>Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in
      participants with high-risk vascular disease (HRVD).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study termination due to insufficient efficacy.
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Composite Primary Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA)</measure>
    <time_frame>Baseline to Study Completion (Up to 4 years)</time_frame>
    <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline to 3 Months in Low-Density (LDL-C) and High-Density Lipoprotein Cholesterol (HDL-C) Levels</measure>
    <time_frame>Baseline, 3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Endpoint of All-Cause Mortality, MI, Stroke, Coronary Revascularization, or Hospitalization for UA</measure>
    <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
    <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Endpoint of CV Death, MI, or Coronary Revascularization</measure>
    <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
    <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA</measure>
    <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
    <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Triple Composite Endpoint of CV Death, MI, or Stroke</measure>
    <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
    <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12092</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Evacetrapib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evacetrapib</intervention_name>
    <description>Administered Orally</description>
    <arm_group_label>Evacetrapib</arm_group_label>
    <other_name>LY2484595</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered Orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of high risk vascular disease (HRVD) (that is, meet at least one of the
             disease diagnostic criteria of: 1)History of acute coronary syndrome (ACS) (that is,
             ≥30 days through 365 days after discharge for ACS) 2)cerebrovascular atherosclerotic
             disease 3)peripheral arterial disease 4)diabetes mellitus with documented coronary
             artery disease and are clinically stable (as judged by the responsible physician).

          -  Must be treated with a statin for at least 30 days prior to screening. If not treated
             with a statin must have documented statin intolerance, or contraindication to statin

          -  Have a screening high-density lipoprotein cholesterol (HDL-C) ≤80 milligram per
             deciliter (mg/dL) (≤2.1 millimole per liter [mmol/L])

          -  Have screening triglycerides (TG) ≤400 mg/dL (≤4.5 mmol/L)

          -  Meet 1 of the following criteria:

               -  screening low-density lipoprotein cholesterol (LDL-C) no more than 10 mg/dL (0.3
                  mmol/L) above the target chosen by the investigator (either LDL-C &lt;100 mg/dL
                  [&lt;2.6 mmol/L] or LDL-C &lt;70 mg/dL [&lt;1.8 mmol/L]), OR

               -  if LDL-C is greater than target, the participant must be on maximum tolerated
                  statin dose (for at least 30 days), have documented statin intolerance, or
                  contraindication to statin

        Exclusion Criteria:

          -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical
             trial involving an investigational product or non-approved use of a drug or device, or
             concurrently enrolled in any other type of medical research judged not to be
             scientifically or medically compatible with this study

          -  Have previously completed or withdrawn from this study, or withdrawn from any other
             study investigating evacetrapib

          -  Female participants who are known to be pregnant or breastfeeding

          -  Women of child-bearing potential only, who test positive for pregnancy between
             screening and randomization, or who do not agree to use a reliable method of birth
             control during the study

          -  History of transient ischemic attack (TIA) or ischemic stroke &lt;30 days and ACS &lt;30
             days

          -  Any reading of systolic blood pressure ≥180 millimeter of mercury (mm Hg) or diastolic
             blood pressure ≥110 mm Hg at screening or randomization

          -  History of hemorrhagic stroke or intracranial hemorrhage

          -  New York Heart Association class III or IV congestive heart failure

          -  Serum creatinine &gt;2.2 mg/dL (&gt;194.5 micromole per liter [μmol/L]) at screening

          -  Clinically active liver disease. Participants are not excluded due to Gilbert's
             Syndrome or a history of cholelithiasis/cholecystectomy

          -  History of malignancy within the preceding 3 years prior to screening

          -  Known malabsorption syndrome with the exception of lactose intolerance

          -  Participants with a known history of primary or secondary hyperaldosteronism

          -  Participants with a history of intolerance/hypersensitivity to cholesterol ester
             transfer protein (CETP) inhibitors

          -  Any clinically significant medical condition that according to the investigator could
             interfere with participation in the study

          -  Participants whose life expectancy is anticipated to be less than 4 years

          -  Unable or unwilling to comply with study requirements, or deemed by the investigator
             to be unfit for the study

          -  Have a history of drug, alcohol, or substance abuse within the past 6 months, as
             assessed by the investigator

          -  Concurrent or anticipated need for treatment with niacin &gt;250 mg/day or for chronic
             administration of drugs on the exclusion list

          -  Previous exposure to the CETP inhibitors dalcetrapib or evacetrapib within the last 3
             months or anacetrapib within the last 12 months

          -  Any planned coronary angiography or coronary revascularization procedure. If
             angiography or revascularization is planned, participants may be screened and enrolled
             after all such planned procedures are completed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cottonwood</city>
        <state>Arizona</state>
        <zip>86326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <zip>32003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>FL</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Safety Harbor</city>
        <state>Florida</state>
        <zip>34695</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Covington</city>
        <state>Georgia</state>
        <zip>30014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cumming</city>
        <state>Georgia</state>
        <zip>30041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bannockburn</city>
        <state>Illinois</state>
        <zip>60015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jerseyville</city>
        <state>Illinois</state>
        <zip>62052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rock Island</city>
        <state>Illinois</state>
        <zip>61201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <zip>46112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hammond</city>
        <state>Indiana</state>
        <zip>46320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hutchinson</city>
        <state>Kansas</state>
        <zip>67502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Natick</city>
        <state>Massachusetts</state>
        <zip>01760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cadillac</city>
        <state>Michigan</state>
        <zip>49601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <zip>49855</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101 2595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elmer</city>
        <state>New Jersey</state>
        <zip>08318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <zip>08035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mine Hill</city>
        <state>New Jersey</state>
        <zip>07803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sewell</city>
        <state>New Jersey</state>
        <zip>08080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saratoga Springs</city>
        <state>New York</state>
        <zip>12866</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Southampton</city>
        <state>New York</state>
        <zip>11968</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Troy</city>
        <state>New York</state>
        <zip>12180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Westfield</city>
        <state>New York</state>
        <zip>14787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lenoir</city>
        <state>North Carolina</state>
        <zip>28645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Port Matilda</city>
        <state>Pennsylvania</state>
        <zip>16870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pottstown</city>
        <state>Pennsylvania</state>
        <zip>19464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Red Lion</city>
        <state>Pennsylvania</state>
        <zip>17356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cumberland</city>
        <state>Rhode Island</state>
        <zip>02864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greeneville</city>
        <state>Tennessee</state>
        <zip>37745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tullahoma</city>
        <state>Tennessee</state>
        <zip>37388</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <zip>78028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Harrisonburg</city>
        <state>Virginia</state>
        <zip>22801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oregon</city>
        <state>Wisconsin</state>
        <zip>53575</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Belgrano</city>
        <zip>C1428DCO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>CBA 1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coronel Suarez</city>
        <zip>B7540GHD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Córdoba</city>
        <zip>5006</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Luis</city>
        <zip>D5702JRS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Miguel De Tucuman</city>
        <zip>T4000NIL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2522</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milton</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3162</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Windsor</city>
        <state>Victoria</state>
        <zip>3183</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Feldkirch</city>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brussels</city>
        <zip>01200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huy</city>
        <zip>4500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tienen</city>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Smolyan</city>
        <zip>4700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1N 2C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 2P7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 6K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 2N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 7C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brossard</city>
        <state>Quebec</state>
        <zip>J4X 1S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y6S9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Joilette</city>
        <state>Quebec</state>
        <zip>J6E 6J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <zip>J4M 2X1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint-Georges</city>
        <state>Quebec</state>
        <zip>G5Y 4T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St-Jerome</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St-Lambert</city>
        <state>Quebec</state>
        <zip>J4P 2H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changsha</city>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guang Zhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Harbin</city>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shenyang</city>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cesky Krumlov</city>
        <zip>381 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hodonin</city>
        <zip>69501</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marianske Lazne</city>
        <zip>35301</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pisek</city>
        <zip>39701</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Prague</city>
        <zip>13000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pribram</city>
        <zip>26101</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Teplice</city>
        <zip>41501</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Copenhagen</city>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tallinn</city>
        <zip>10128</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Viljandi</city>
        <zip>71024</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tübingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warendorf</city>
        <zip>48231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Central</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Debrecen</city>
        <zip>4025</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hodmezovasarhely</city>
        <zip>6800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kalocsa</city>
        <zip>H-6300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Komarom</city>
        <zip>2921</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oroshaza</city>
        <zip>5901</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szekszard</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jerusalem</city>
        <zip>91004</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nazareth</city>
        <zip>16100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Safed</city>
        <zip>13110</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Castelfranco Veneto</city>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chieti Scalo</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Daniele Del Friuli</city>
        <zip>33038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sessa Aurunca</city>
        <zip>81037</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>270-2251</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ehime</city>
        <zip>798-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gunma</city>
        <zip>377-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>665-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ibaraki</city>
        <zip>311-3193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ishikawa</city>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyoto</city>
        <zip>661-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Okinawa</city>
        <zip>901-0493</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>581-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saitama</city>
        <zip>351-0102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shizuoka</city>
        <zip>411-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8539</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yamaguchi</city>
        <zip>740-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chungbuk</city>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gangwon-Do</city>
        <zip>200-722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goyang</city>
        <zip>410-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gwangju</city>
        <zip>510-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-10323</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chihuahua</city>
        <zip>31238</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cul Sinaloa</city>
        <zip>80020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huixquilucan</city>
        <zip>52763</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78216</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampico</city>
        <zip>89000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tijuana</city>
        <zip>22500</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Amersfoort</city>
        <zip>3818 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beverwijk</city>
        <zip>1942 LE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Den Helder</city>
        <zip>1782 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Drachten</city>
        <zip>9202 NN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heerlen</city>
        <zip>6401CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hilversum</city>
        <zip>1213 XZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hoogeveen</city>
        <zip>7909AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hoorn</city>
        <zip>1625 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>S-Hertogenbosch</city>
        <zip>5223 GV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waalwijk</city>
        <zip>5141 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zaandam</city>
        <zip>1502 DV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Addington</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Grafton</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamilton West</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newtown</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tauranga</city>
        <zip>3140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Westlake</city>
        <zip>0620</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-863</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-126</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kutno</city>
        <zip>99-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lodz</city>
        <zip>94-255</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Olawa</city>
        <zip>55-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pulawy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sobotka</city>
        <zip>55050</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-112</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ponce</city>
        <zip>00717-1322</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Trujillo Alto</city>
        <zip>00976</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Braila</city>
        <zip>810249</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buzau</city>
        <zip>120203</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Focsani</city>
        <zip>620034</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oradea</city>
        <zip>410169</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>111020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196105</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tomsk</city>
        <zip>196105</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bardejov</city>
        <zip>08501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kralovsky Chlmec</city>
        <zip>07701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zilina</city>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alberton</city>
        <zip>1449</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellville</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goodwood</city>
        <zip>7460</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Johannesburg</city>
        <zip>1460</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kuilsriver</city>
        <zip>7580</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newlands West</city>
        <zip>4035</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Parktown West</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>L´Hospitalet De Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lund</city>
        <zip>22221</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stockholm</city>
        <zip>11157</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Östersund</city>
        <zip>83183</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lugano</city>
        <zip>CH-6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kuei Shan Hsiang</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>111</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ankara</city>
        <zip>06520</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Konya</city>
        <zip>42250</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyiv</city>
        <zip>2091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lutsk</city>
        <zip>43024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poltava</city>
        <zip>36038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St. Stephen</city>
        <state>Cornwall</state>
        <zip>PL26 7RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Welwyn Garden City</city>
        <state>Hertfordshire</state>
        <zip>AL7 4HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barnet</city>
        <state>Herts</state>
        <zip>EN5 3DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stevenage</city>
        <state>Herts</state>
        <zip>SG4 7NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tooting</city>
        <state>London</state>
        <zip>SW17 ORE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wellingborough</city>
        <state>Northants</state>
        <zip>NN8 4RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dudley</city>
        <state>West Midlands</state>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bath</city>
        <zip>BA2 4BY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frome</city>
        <zip>BA11 1EZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>India</country>
    <country>Peru</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2012</study_first_posted>
  <results_first_submitted>February 18, 2018</results_first_submitted>
  <results_first_submitted_qc>April 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 16, 2018</results_first_posted>
  <disposition_first_submitted>August 13, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>August 13, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 16, 2016</disposition_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evacetrapib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly, in collaboration with the Cleveland Clinic Coordinating Center for Clinical Research (C5Research) will provide access to the individual patient data from the ACCELERATE trial to enable the advancement of cardiovascular research. Proposals will be accepted beginning May 2018. This access is provided in a timely fashion after the primary publication. Researchers need to have an approved research proposal submitted through http://c5research.clevelandclinic.org/ACCELERATE-data.aspx
Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Non-Completers: Participants &quot;Known to be Alive at Study End&quot; is a subset of those who did not withdraw consent and later found to be alive from public sources. &quot;Lost to follow-up&quot; is a subset of those who did not withdraw consent for whom study end vital status could not be ascertained.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Evacetrapib</title>
          <description>Evacetrapib 130 milligram (mg) tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6038"/>
                <participants group_id="P2" count="6054"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="6036"/>
                <participants group_id="P2" count="6052"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5926"/>
                <participants group_id="P2" count="5934"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Known to be Alive at Study End</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Evacetrapib</title>
          <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6038"/>
            <count group_id="B2" value="6054"/>
            <count group_id="B3" value="12092"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.791" spread="9.3849"/>
                    <measurement group_id="B2" value="64.994" spread="9.4591"/>
                    <measurement group_id="B3" value="64.892" spread="9.4223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1390"/>
                    <measurement group_id="B2" value="1394"/>
                    <measurement group_id="B3" value="2784"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4648"/>
                    <measurement group_id="B2" value="4660"/>
                    <measurement group_id="B3" value="9308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="522"/>
                    <measurement group_id="B3" value="1022"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5394"/>
                    <measurement group_id="B2" value="5386"/>
                    <measurement group_id="B3" value="10780"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="469"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="650"/>
                    <measurement group_id="B2" value="640"/>
                    <measurement group_id="B3" value="1290"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="294"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4933"/>
                    <measurement group_id="B2" value="4971"/>
                    <measurement group_id="B3" value="9904"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2235"/>
                    <measurement group_id="B2" value="2240"/>
                    <measurement group_id="B3" value="4475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="626"/>
                    <measurement group_id="B2" value="619"/>
                    <measurement group_id="B3" value="1245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Composite Primary Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA)</title>
        <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
        <time_frame>Baseline to Study Completion (Up to 4 years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib</title>
            <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Primary Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA)</title>
          <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6038"/>
                <count group_id="O2" value="6054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="779"/>
                    <measurement group_id="O2" value="776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Endpoint: Time to First Occurrence of the Composite Primary Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9054</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.006</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.911</ci_lower_limit>
            <ci_upper_limit>1.111</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline to 3 Months in Low-Density (LDL-C) and High-Density Lipoprotein Cholesterol (HDL-C) Levels</title>
        <time_frame>Baseline, 3 Months</time_frame>
        <population>All randomized participants with evaluable LDL-C and HDL-C levels.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib</title>
            <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline to 3 Months in Low-Density (LDL-C) and High-Density Lipoprotein Cholesterol (HDL-C) Levels</title>
          <population>All randomized participants with evaluable LDL-C and HDL-C levels.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6038"/>
                <count group_id="O2" value="6054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5760"/>
                    <count group_id="O2" value="5786"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.12" spread="27.583"/>
                    <measurement group_id="O2" value="5.99" spread="29.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5760"/>
                    <count group_id="O2" value="5788"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.18" spread="57.204"/>
                    <measurement group_id="O2" value="1.63" spread="17.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LDL-C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-37.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.15</ci_lower_limit>
            <ci_upper_limit>-36.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HDL-C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>131.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>130.01</ci_lower_limit>
            <ci_upper_limit>133.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Endpoint of All-Cause Mortality, MI, Stroke, Coronary Revascularization, or Hospitalization for UA</title>
        <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
        <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib</title>
            <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Endpoint of All-Cause Mortality, MI, Stroke, Coronary Revascularization, or Hospitalization for UA</title>
          <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6038"/>
                <count group_id="O2" value="6054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="857"/>
                    <measurement group_id="O2" value="867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to First Occurrence of the Composite Endpoint of All-Cause Mortality, MI, Stroke, Coronary Revascularization, or Hospitalization for UA</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8463</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.991</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.901</ci_lower_limit>
            <ci_upper_limit>1.089</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Endpoint of CV Death, MI, or Coronary Revascularization</title>
        <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
        <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib</title>
            <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Endpoint of CV Death, MI, or Coronary Revascularization</title>
          <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6038"/>
                <count group_id="O2" value="6054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="690"/>
                    <measurement group_id="O2" value="691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to First Occurrence of the Composite Endpoint of CV Death, MI, or Coronary Revascularization</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9874</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.901</ci_lower_limit>
            <ci_upper_limit>1.112</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA</title>
        <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
        <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib</title>
            <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA</title>
          <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6038"/>
                <count group_id="O2" value="6054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="571"/>
                    <measurement group_id="O2" value="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to First Occurrence of the Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9574</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.003</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.893</ci_lower_limit>
            <ci_upper_limit>1.127</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Triple Composite Endpoint of CV Death, MI, or Stroke</title>
        <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
        <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib</title>
            <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Triple Composite Endpoint of CV Death, MI, or Stroke</title>
          <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6038"/>
                <count group_id="O2" value="6054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437"/>
                    <measurement group_id="O2" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to First Occurrence of Triple Composite Endpoint of CV Death, MI, or Stroke</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5917</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.965</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.846</ci_lower_limit>
            <ci_upper_limit>1.100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>Evacetrapib</title>
          <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2306" subjects_at_risk="6036"/>
                <counts group_id="E2" subjects_affected="2341" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="30" subjects_at_risk="6036"/>
                <counts group_id="E2" events="46" subjects_affected="38" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aplastic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spontaneous haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="168" subjects_affected="146" subjects_at_risk="6036"/>
                <counts group_id="E2" events="149" subjects_affected="137" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adams-stokes syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="113" subjects_affected="102" subjects_at_risk="6036"/>
                <counts group_id="E2" events="103" subjects_affected="98" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="389" subjects_affected="298" subjects_at_risk="6036"/>
                <counts group_id="E2" events="363" subjects_affected="289" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic valve sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="109" subjects_affected="86" subjects_at_risk="6036"/>
                <counts group_id="E2" events="94" subjects_affected="78" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="6036"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="6036"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="79" subjects_affected="67" subjects_at_risk="6036"/>
                <counts group_id="E2" events="78" subjects_affected="63" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="134" subjects_affected="95" subjects_at_risk="6036"/>
                <counts group_id="E2" events="138" subjects_affected="103" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronotropic incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="40" subjects_affected="37" subjects_at_risk="6036"/>
                <counts group_id="E2" events="45" subjects_affected="44" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="88" subjects_affected="82" subjects_at_risk="6036"/>
                <counts group_id="E2" events="107" subjects_affected="100" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postinfarction angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Systolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="6036"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wolff-parkinson-white syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Leukodystrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Conductive deafness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ectropion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Entropion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Idiopathic orbital inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Keratopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lens dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Optic atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Optic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal wall cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coeliac artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colonic fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dieulafoy's vascular malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastritis alcoholic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="6036"/>
                <counts group_id="E2" events="32" subjects_affected="26" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Heyde's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Jejunal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Localised intraabdominal fluid collection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mallory-weiss syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mesenteric vascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oedematous pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retroperitoneal effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Salivary gland mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tongue haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="38" subjects_affected="37" subjects_at_risk="6036"/>
                <counts group_id="E2" events="42" subjects_affected="34" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device end of service</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device inappropriate shock delivery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device material issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Exercise tolerance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Implant site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ischaemic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lead dislodgement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Necrobiosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="123" subjects_affected="107" subjects_at_risk="6036"/>
                <counts group_id="E2" events="118" subjects_affected="108" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Precancerous mucosal lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular stent stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular stent thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="6036"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6036"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="6036"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Jaundice extrahepatic obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal wall infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abscess of salivary gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriosclerotic gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteritis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="6036"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="48" subjects_affected="41" subjects_at_risk="6036"/>
                <counts group_id="E2" events="45" subjects_affected="42" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholangitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Clostridium difficile sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endocarditis enterococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enterobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4648"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Escherichia pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gallbladder abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="6036"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>H1n1 influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatitis c</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Implant site cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infected fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infected seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infusion site cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infusion site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Keratitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nail bed infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Orbital infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteomyelitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Parvovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Penile abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Perihepatic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="128" subjects_affected="115" subjects_at_risk="6036"/>
                <counts group_id="E2" events="122" subjects_affected="112" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia chlamydial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia parainfluenzae viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="49" subjects_affected="44" subjects_at_risk="6036"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Staphylococcal mediastinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="6036"/>
                <counts group_id="E2" events="36" subjects_affected="32" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Viral labyrinthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anastomotic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anastomotic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chemical burn of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chemical injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Crush injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="40" subjects_affected="39" subjects_at_risk="6036"/>
                <counts group_id="E2" events="53" subjects_affected="50" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Muscle contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nerve root injury lumbar</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral arterial reocclusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery restenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post concussion syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post laminectomy syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative thoracic procedure complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Stoma site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Traumatic amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Angiogram</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriogram</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6036"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriogram renal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Biopsy brain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood osmolarity decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac function test</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiovascular evaluation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiovascular examination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid bruit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Clostridium test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colonoscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Computerised tomogram</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Computerised tomogram thorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diagnostic procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Electrocardiogram qt prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endoscopy gastrointestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>International normalised ratio decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myocardial necrosis marker increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophagogastroduodenoscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral arteriogram</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ureteroscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vitamin b12 decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6036"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperosmolar hyperglycaemic state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="6036"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vitamin b12 deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Facet joint syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Kyphosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ligament laxity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6036"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="76" subjects_affected="70" subjects_at_risk="6036"/>
                <counts group_id="E2" events="75" subjects_affected="66" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adenosquamous cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anaplastic astrocytoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="6036"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Benign gastric neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of adrenal gland</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of spinal cord</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Benign renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Borderline mucinous tumour of ovary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchial neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Burkitt's lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Buschke-lowenstein's tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the gastrointestinal tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon cancer stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon cancer stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon cancer stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colorectal cancer stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Desmoplastic melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma stage ii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma stage iii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ewing's sarcoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fallopian tube cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gallbladder adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gingival cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Keratinising squamous cell carcinoma of nasopharynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Large intestine benign neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Laryngeal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage i</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage ii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage ii</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="6036"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage i</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphocytic lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant fibrous histiocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mediastinum neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Meningioma malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastases to salivary gland</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myxofibrosarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nasal sinus cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage iiia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oral cavity cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oropharyngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatic neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Papillary cystadenoma lymphomatosum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Phaeochromocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="4648"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage ii</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4648"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinonasal papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the vulva</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Testicular neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Testicular seminoma (pure)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thymoma malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tongue carcinoma stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tonsil cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Uterine neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute disseminated encephalomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Brain mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="6036"/>
                <counts group_id="E2" events="42" subjects_affected="39" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebellar ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebellar syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="63" subjects_affected="61" subjects_at_risk="6036"/>
                <counts group_id="E2" events="65" subjects_affected="62" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Essential tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhagic transformation stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="6036"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Moyamoya disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postictal paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Quadriplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="48" subjects_affected="46" subjects_at_risk="6036"/>
                <counts group_id="E2" events="54" subjects_affected="52" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="44" subjects_affected="37" subjects_at_risk="6036"/>
                <counts group_id="E2" events="42" subjects_affected="39" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Uraemic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vasogenic cerebral oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vertebral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vertigo cns origin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Viith nerve paralysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vith nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vith nerve paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with mixed disturbance of emotion and conduct</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Psychogenic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="58" subjects_affected="48" subjects_at_risk="6036"/>
                <counts group_id="E2" events="81" subjects_affected="67" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cystitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Glomerulosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypotonic urinary bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="6036"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nephrosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pelvi-ureteric obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ureteral disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urethral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="4648"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1388"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Penile necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Peyronie's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="4648"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Testicular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1388"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="6036"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="55" subjects_affected="43" subjects_at_risk="6036"/>
                <counts group_id="E2" events="55" subjects_affected="47" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="6036"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mediastinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="6036"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="6036"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tracheomalacia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dermatomyositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Henoch-schonlein purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vasculitic rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adrenalectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Analgesic therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aneurysm repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ankle arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm repair</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic valve repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic valve replacement</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atherectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrial septal defect repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Autonomic nerve operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder neck suspension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bone operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchial lesion excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cancer surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac ablation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker battery replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac rehabilitation therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac resynchronisation therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardioversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid angioplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid endarterectomy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid revascularisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Catheter placement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colectomy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colostomy closure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="6036"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="54" subjects_affected="54" subjects_at_risk="6036"/>
                <counts group_id="E2" events="59" subjects_affected="59" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="92" subjects_affected="82" subjects_at_risk="6036"/>
                <counts group_id="E2" events="89" subjects_affected="79" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cox-maze procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Debridement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diaphragmatic operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Elective surgery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endarterectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endovenous ablation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Explorative laparotomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Exploratory operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Eye operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Foot amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal endoscopic therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haematoma evacuation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Heart valve replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>High frequency ablation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hip surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Incisional drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Incisional hernia repair</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intervertebral disc operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intraocular lens implant</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="6036"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lens extraction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lipoma excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Medical device change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mitral valve replacement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Open reduction of fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteosynthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteotomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreaticoduodenectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Penile repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" events="217" subjects_affected="192" subjects_at_risk="6036"/>
                <counts group_id="E2" events="214" subjects_affected="182" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery angioplasty</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery bypass</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral endarterectomy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral nerve transposition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral revascularisation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prostate ablation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prostatectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Radioactive iodine therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal prolapse repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal artery angioplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal sympathetic nerve ablation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Resection of rectum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Resuscitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retinopexy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Shoulder arthroplasty</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sympathectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tenotomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Therapeutic embolisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Therapy cessation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombectomy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombosis prophylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tongue operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Total adrenalectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transmyocardial revascularisation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transurethral bladder resection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4648"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Tricuspid valve repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tumour excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ureteral stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ureteral stent removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Valvuloplasty cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular graft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Venous stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular assist device insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic elongation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="6036"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Axillary vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Brachiocephalic artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Femoral artery perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="6036"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Iliac artery rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphatic fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="66" subjects_affected="52" subjects_at_risk="6036"/>
                <counts group_id="E2" events="66" subjects_affected="50" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="6036"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subclavian artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subclavian artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2659" subjects_at_risk="6036"/>
                <counts group_id="E2" subjects_affected="2529" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="568" subjects_affected="472" subjects_at_risk="6036"/>
                <counts group_id="E2" events="484" subjects_affected="414" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="456" subjects_affected="363" subjects_at_risk="6036"/>
                <counts group_id="E2" events="443" subjects_affected="375" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="603" subjects_affected="452" subjects_at_risk="6036"/>
                <counts group_id="E2" events="602" subjects_affected="465" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="397" subjects_affected="327" subjects_at_risk="6036"/>
                <counts group_id="E2" events="410" subjects_affected="327" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="426" subjects_affected="375" subjects_at_risk="6036"/>
                <counts group_id="E2" events="425" subjects_affected="370" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="442" subjects_affected="399" subjects_at_risk="6036"/>
                <counts group_id="E2" events="412" subjects_affected="379" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="412" subjects_affected="339" subjects_at_risk="6036"/>
                <counts group_id="E2" events="388" subjects_affected="329" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="435" subjects_affected="389" subjects_at_risk="6036"/>
                <counts group_id="E2" events="407" subjects_affected="352" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="367" subjects_affected="327" subjects_at_risk="6036"/>
                <counts group_id="E2" events="304" subjects_affected="279" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="339" subjects_affected="305" subjects_at_risk="6036"/>
                <counts group_id="E2" events="341" subjects_affected="307" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="508" subjects_affected="453" subjects_at_risk="6036"/>
                <counts group_id="E2" events="466" subjects_affected="403" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

